(Q40706078)

22 September 2017

title

Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients (English)

1 reference

22 September 2017

main subject

phase III clinical trial

0 references

1 reference

Ji-Dong Jia

1

1 reference

22 September 2017

Jin-Lin Hou

2

1 reference

22 September 2017

You-Kuan Yin

3

1 reference

22 September 2017

De-Ming Tan

4

1 reference

22 September 2017

Daozhen Xu

5

1 reference

22 September 2017

Jun-Qi Niu

6

1 reference

22 September 2017

Xia-Qiu Zhou

7

1 reference

22 September 2017

Yu-Ming Wang

8

1 reference

22 September 2017

Li-Min Zhu

9

1 reference

22 September 2017

Cheng-Wei Chen

10

1 reference

22 September 2017

Yong-Wen He

11

1 reference

22 September 2017

Hong Ren

12

1 reference

22 September 2017

Mo-Bin Wan

13

1 reference

22 September 2017

Shan-Ming Wu

14

1 reference

22 September 2017

Qin-Huan Wang

15

1 reference

22 September 2017

Lai Wei

16

1 reference

22 September 2017

Weibin Bao

17

1 reference

22 September 2017

Yuhong Dong

18

1 reference

22 September 2017

Aldo Trylesinski

19

1 reference

22 September 2017

publication date

28 November 2013

1 reference

22 September 2017

published in

Hepatology international

1 reference

22 September 2017

volume

8

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

72-82

1 reference

https://scigraph.springernature.com/pub.10.1007/s12072-013-9488-2

22 September 2017

exact match

0 references

cites work

Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Model of life expectancy of chronic hepatitis B carriers in an endemic region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Hepatitis B virus DNA levels and outcomes in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Natural history of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9488-2

Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B

21 January 2018

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China

1 reference

PubMed

12 December 2020

Telbivudine preserves T-helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis

1 reference

PubMed

12 December 2020

10.1007/S12072-013-9488-2

Identifiers

DOI

1 reference

22 September 2017

1 reference